Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH MM 2018 | Combining bortezomib and lenalidomide-based regimens for frontline MM

Frontline transplant-ineligible multiple myeloma (MM) is typically treated with VMP (bortezomib, melphalan, prednisolone) or Rd (lenalidomide, dexamethasone) based regimens. However, efforts have recently been made to combine these treatments, as discussed here by Kwee Yong, PhD, FRCP, FRCPath, from University College London, London, UK. Prof. Yong highlights the RVd (lenalidomide, bortezomib, dexamethasone) lite treatment protocol, as well as alternating or sequential regimens.